Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Peter Marks
Biotech
Former CBER chief Peter Marks leaps to Lilly—Chutes & Ladders
Former CBER chief Peter Marks leaps to Lilly. OSE swaps out CEO. Mikael Dolsten settles into board chair at cancer biotech.
Darren Incorvaia
,
Zoey Becker
Oct 10, 2025 8:30am
Former FDA official Peter Marks joins Eli Lilly
Oct 7, 2025 3:49pm
FDA proposes new approval pathway for rare diseases
Sep 3, 2025 1:20pm
Fierce Pharma
FDA's acting CDER head heads for the exit: report
Jun 23, 2025 1:48pm
FDA leadership 'decapitated,' former leader Janet Woodcock says
Apr 7, 2025 4:04pm
FDA's new platform guidance aims to smooth regulatory encounters
May 30, 2024 7:30am
